Exocin™ Abbreviated Prescribing Information
Presentation: A clear, odourless aqueous ophthalmic solution of ofloxacin 0.3% (w/v). **Indications:** EXOCIN is indicated for the topical treatment of external ocular infections (such as conjunctivitis and keratoconjunctivitis) in adults and children caused by ofloxacin-sensitive organisms. Safety and efficacy in the treatment of ophthalmia neonatorum has not been established. **Dosage and administration:** For all ages: One to two drops in the affected eye(s) every two to four hours for the first two days, and then four times daily. The length of treatment should not exceed ten days. **Pharmacology:** Ofloxacin is a synthetic fluorinated 4-quinolone antibacterial agent. **Contraindications:** EXOCIN is contraindicated in patients sensitive to ofloxacin or any of its other components.

exoci

infecti

out

Use during pregnancy: There have been no adequate and well-controlled studies performed in pregnant women. Since systemic quinolones have been shown to cause arthropathy in immature animals, it is recommended that EXOCIN be used in pregnant women only if the potential benefit justifies the potential risk to the foetus. Use during lactation: Because ofloxacin and other quinolones taken systemically are excreted in breast milk and there is potential for harm to nursing infants a decision should be made whether to temporarily discontinue nursing or not to administer the drug, taking into account the importance of the drug to the mother. Precautions: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms. If worsening infection occurs, or if clinical improvement is not noted within a reasonable period, discontinue use and institute alternative therapy. Use EXOCIN with caution in patients who have exhibited sensitivities to other quinolone antibacterial agents. EXOCIN should not be used while patients are wearing hyorophilic (soft) contact lenses. Adverse reactions: Transient ocular irritation has been reported. Since ofloxacin is systemically absorbed after topical administration, side effects reported with systemic use could possibly occur. Overdosage: In the event of a topical overdosage, flush eye with water. **Legal category:** POM **Package quantities:** EXOCIN is supplied in plastic dropper bottles containing 5 ml solution. Basic NHS Price £2.27. **Further information:** The primary mechanism of action is through inhibition of bacterial DNA gyrase, the enzyme responsible for maintaining the structure of DNA. **Product licence number:** 0426/0070. **References:**
1. Osato M.S. et al., Am. J. Ophthal. (1989) 108:380-386 **2.** Crumpton G.C., Ode. M., Drugs 34 (Suppl 1): 1-8 (1987) **3.** Brown A.J. et al., B.J. Ophthal. (1991) 75:675-679

EXOCIN is an ocular quinolone antibiotic with a dual mode of action, which offers extra reassurance when treating in the absence of bacteriological identification. With potent bactericidal activity(1) against most gram +ve and gram -ve organisms, including Staphylococci and Pseudomonas, you can be confident that EXOCIN drops will deal with infections quickly and effectively.

And because EXOCIN's action on bacterial DNA gyrase has been shown to deter the development of resistance (2), there's no need to consider it as a 'reserve'. Indeed, with the increasing resistance to chloramphenicol(3) EXOCIN should be considered as your first choice in the treatment of eye infections.

exocin™

ofloxacin

ALLERGAN

Allergan Limited
High Wycombe
Bucks HP12 3SH
United Kingdom

Date of Preparation: June 1994

AL/047/93 TM Trade Mark

Voltarol® Ophtha Abridged Prescribing Information

Presentation: Sterile eye drop solution containing 0.1% (w/v) diclofenac sodium in a preservative free formulation in single dose units.
Uses: Inhibition of peroperative miosis during cataract surgery. Post-operative inflammation in cataract surgery.
Dosage and Administration: *Adults and Elderly.* Propiylaxis of peroperative miosis: 1 drop four times during the 2 hours prior to surgery. Post-operative inflammation: 1 drop four times daily for up to 10 days. *Children:* Not established. Note: Each Voltarol Ophtha single dose unit should be used for a single dose only. Discard the single dose anit immediately after use.
Contra-indications: Hypersensitivity to any of the ingredients. Like other NSAIDs, patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibiting activity. Intraocular use during surgical procedure.
Precautions: In the presence of infection or risk of infection, appropriate therapy (eg antibiotic) should be given concurrently with Voltarol Ophtha. Use with caution in patients receiving other medications which may prolong bleeding time, or with known haemostatic defects.
Adverse Reactions: Most frequently, mild to moderate burning sensation. Rarely, blurred vision immediately after instillation, hypersensitivity reactions with itching and reddening, photosensitivity, keratitis punctata.
Use during pregnancy and lactation: There is no experience concerning the safety of Voltarol Ophtha in human pregnancy or lactation. Administration is therefore not recommended except for compelling reasons.
Ability to drive and operate machinery: Patients with blurred vision should refrain from driving a vehicle or operating machinery.
Distributed by, and further information on request from: CIBA Vision Ophthalmics, Ledge End, Southampton SO3 3LG.
PL Holder: Ciba-Geigy plc, Macclesfield, Cheshire.
Package quantities and basic NHS price: 4 x 0.3 ml SDUs £3.99, 40 x 0.3 ml SDUs £39.90 (PL 0001/172)
Legal Category: POM
® denotes registered trademark of Ciba-Geigy
Date of preparation: October 1992

CIBAVision Ophthalmics

DH01A01/93

Voltarol®
Ophtha SDUs
diclofenac sodium solution 0.1% w/v

maintains mydriasis
controls post-cataract surgery inflammation

NEW
The OBF Tonograph — Measures Dynamic IOP and Pulsatile Ocular Blood Flow



Some preliminary papers have been prepared which suggest that a correlation exists between low ocular blood flow and the incidence of glaucoma.
The OBF Tonograph is a new generation instrument which allows the study of ocular blood flow using advanced real-time analysis techniques to construct an image of each pulse.

For an information pack please call Caroline Moore on 0279 414969.

Clement Clarke & OBF Labs (UK) – *Partners in Quality*

HS INTERNATIONAL

Clement Clarke

A HAAG-STREIT COMPANY

Clement Clarke International Ltd. Airmed House, Edinburgh Way, Harlow, Essex CM20 2ED, UK.
Tel: +44 (0) 279 414969 Fax: +44 (0) 279 635232 Telex: 81338

HOLD IT RIGHT THERE



Ocufen™

(flurbiprofen sodium 0.03%)

Contains Preservative Free Liquifilm Tears®

RELIABLE PUPIL CONTROL

Prescribing Information: OCUFEN™ Presentation: Clear, colourless, sterile ophthalmic solution in unit dose presentation, containing flurbiprofen sodium USP 0.03% (w v)and Liquifilm (polyvinyl alcohol USP) 1.4% (w v). Also contains potassium chloride PhEur, sodium chloride PhEur, sodium citrate dihydrate PhEur, citric acid monohydrate PhEur and purified water PhEur. **Uses:** Ocufen is indicated for the inhibition of intraoperative miosis. Ocufen does not have intrinsic mydriatic properties and does not replace standard mydriatic therapy. **Dosage and administration:** *Adults:* Ocufen should be instilled into the eye scheduled for surgery at a rate of one drop every half hour, commencing 2 hours prior to operation (4 drops in total). The final drop should be given not less than 30 minutes before surgery. In accordance with standard practice, other topical medication should not be co-administered with Ocufen. When administering other topical pre-operative medications, a minimum interval of 5 minutes between instillations is recommended. Each vial of Ocufen should be used for a single dose and discarded after use. *Use in children:* Safety and effectiveness in children have not been established. **Contra-indications, warning etc.** *Contra-indications:* Ocufen is contra-indicated in epithelial herpes simplex keratitis (dendritic keratitis) and in individuals hypersensitive to any component of the medication. The potential exists for cross-sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. Ocufen is contra-indicated in individuals who have previously exhibited sensitivities to these drugs. Use of Ocufen is contra-indicated in patients with known haemostatic defects or who are receiving other medications which may prolong bleeding time. Ocufen is contra-indicated for intraocular use during surgical procedures. *Warnings:* Wound healing may be delayed with the use of Ocufen. There have been reports that Ocufen may cause an increased bleeding tendency of ocular tissues in conjunction with surgery. *Use in pregnancy:* Safety of use in pregnant women has not been established. Ocufen should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. *Precautions:* Patients with a history of herpes simplex keratitis should be monitored closely. *Adverse reactions:* The most frequent adverse reactions reported with the use of Ocufen are transient burning and stinging on instillation, and other minor signs of ocular irritation. *Drug interaction:* Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in some surgical patients treated with Ocufen. **Pharmaceutical precautions:** Store at or below 25°C. Discard after single use. **Legal category:** POM. **Package quantities:** Ocufen is supplied in unit dose vials, presented in pouches of 4 vials. Each pouch is sufficient for the treatment of one patient. A carton contains 10 pouches. **Further information:** Sodium flurbiprofen is believed to exert its activity through inhibition of the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. Prostaglandins appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, Ocufen has been shown to inhibit miosis induced during surgery, which is of particular benefit during surgical procedures requiring access via the pupil.In clinical studies Ocufen has been used in pre- and peri-operative regimes which included mydriatics (tropicamide, cyclopentolate, phenylephrine, adrenaline); local and general anaesthetics; irrigation solutions; sodium hyaluronate; acetylcholine; and topical antibiotics (neomycin, erythromycin, bacitracin and gentamicin). **Basic NHS Price**: £38.90 for 10 x (4 x 0.4ml). **Product licence number**: 0426/0069 **Allergan Limited** High Wycombe Bucks. HP12 3SH. **Date of preparation**: January 1994